Product of LSP’s portfolio company GTX medical restores walking in humans with spinal cord injury



Amsterdam, The Netherlands, November 1, 2018 – LSP’s portfolio company GTX medical is developing a groundbreaking product to restore walking in spinal cord injury patients. This week, two articles were published in leading scientific journals, Nature and Nature Neuroscience, with the initial results of the prototype in the first chronic spinal cord injury patients. The results are unprecedented, very exciting and promising, demonstrating restoration of walking capabilities in these patients after implantation of the neurostimulation device followed by a training period of the patients. 
 
The results and scientific publications were covered by various media throughout the world, of which some examples are given below: 
 
- https://www.sciencenews.org/article/stimulating-spinal-cord-helps-more-paralyzed-people-walk
- https://www.cbsnews.com/news/paralyzed-patients-walk-again-with-help-of-spinal-implant/  
- https://www.bbc.com/news/health-46043924  
- https://www.theguardian.com/science/2018/oct/31/paralysed-men-can-stand-and-walk-after-electrical-stimulation
- https://www.volkskrant.nl/wetenschap/-grandioos-resultaat-dwarslaesiepatienten-kunnen-na-elektrische-stimulatie-weer-een-beetje-lopen~b936de185/   
- https://nos.nl/l/2257289
 
GTX medical is based on the technology developed by Professor Gregoire Courtine of the leading Swiss institute EPFL (École Polytechnique Fédérale de Lausanne). The company is currently advancing optimization of the technology as well as testing the product in a larger group of patients, including patients with a fresh spinal cord injury, as the clinical benefit is expected to be even larger in this group compared to the chronic lesions that were tested in the initial study. For more information on GTX medical, please visit www.gtxmedical.com
 
About LSP
LSP (Life Sciences Partners) is an independent European investment firm, providing financing for private and public life sciences companies. LSP’s mission is to connect investors to inventors, focusing on unmet medical needs. Since the late 1980s, the LSP team has invested in about 100 innovative enterprises, many of which have grown to become leaders of the global life sciences industry. With over € 2.0 billion ($2.3 billion) of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is Europe’s leading life sciences investor. LSP also invests in public companies through its Euronext-listed LSP Life Sciences Fund (Bloomberg: LSP NA). For more information, please visit www.lspvc.com
 
Contact:
Dr. John P. de Koning
Partner LSP
+31 20 6645500
wqrxbavat@yfcip.pbz
« back to overview
Follow us

Product of LSP’s portfolio company GTX medical restores walking in humans with spinal cord injury



Amsterdam, The Netherlands, November 1, 2018 – LSP’s portfolio company GTX medical is developing a groundbreaking product to restore walking in spinal cord injury patients. This week, two articles were published in leading scientific journals, Nature and Nature Neuroscience, with the initial results of the prototype in the first chronic spinal cord injury patients. The results are unprecedented, very exciting and promising, demonstrating restoration of walking capabilities in these patients after implantation of the neurostimulation device followed by a training period of the patients. 
 
The results and scientific publications were covered by various media throughout the world, of which some examples are given below: 
 
- https://www.sciencenews.org/article/stimulating-spinal-cord-helps-more-paralyzed-people-walk
- https://www.cbsnews.com/news/paralyzed-patients-walk-again-with-help-of-spinal-implant/  
- https://www.bbc.com/news/health-46043924  
- https://www.theguardian.com/science/2018/oct/31/paralysed-men-can-stand-and-walk-after-electrical-stimulation
- https://www.volkskrant.nl/wetenschap/-grandioos-resultaat-dwarslaesiepatienten-kunnen-na-elektrische-stimulatie-weer-een-beetje-lopen~b936de185/   
- https://nos.nl/l/2257289
 
GTX medical is based on the technology developed by Professor Gregoire Courtine of the leading Swiss institute EPFL (École Polytechnique Fédérale de Lausanne). The company is currently advancing optimization of the technology as well as testing the product in a larger group of patients, including patients with a fresh spinal cord injury, as the clinical benefit is expected to be even larger in this group compared to the chronic lesions that were tested in the initial study. For more information on GTX medical, please visit www.gtxmedical.com
 
About LSP
LSP (Life Sciences Partners) is an independent European investment firm, providing financing for private and public life sciences companies. LSP’s mission is to connect investors to inventors, focusing on unmet medical needs. Since the late 1980s, the LSP team has invested in about 100 innovative enterprises, many of which have grown to become leaders of the global life sciences industry. With over € 2.0 billion ($2.3 billion) of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is Europe’s leading life sciences investor. LSP also invests in public companies through its Euronext-listed LSP Life Sciences Fund (Bloomberg: LSP NA). For more information, please visit www.lspvc.com
 
Contact:
Dr. John P. de Koning
Partner LSP
+31 20 6645500
wqrxbavat@yfcip.pbz
« back to overview